Invivyd completes enrollment in two VYD2311 pivotal trials, reports Q2 2026 results

Invivyd, Inc. reported financial results for the quarter ended June 30, 2026 on August 13, 2026, alongside updates on its VYD2311 pivotal program. The DECLARATION pivotal trial, part of Invivyd's REVOLUTION development program for VYD2311, achieved full initial enrollment in March 2026, and after a sample size re-estimation analysis in April 2026, the company announced completion of enrollment in the upsized trial in June 2026, with top-line data planned later in Q3 2026.¹

The LIBERTY trial, a Phase 3 study comparing VYD2311 to an mRNA COVID vaccine and evaluating co-administration safety and immunology, had its first participants dosed and completed enrollment in June 2026, and is now fully dosed, with top-line data anticipated in late Q3 2026.¹

On the regulatory side, Invivyd announced in July 2026 that it received twelve months' advance notice of emergency use authorization termination for PEMGARDA and is in dialogue with the FDA about next steps.¹ Separately, the U.S. Department of Health and Human Services announced on June 30, 2026 the termination of the COVID-19 emergency declaration, effective June 29, 2027.¹

The company also agreed with the FDA on an initial pediatric study plan, DRUMMER, to support a potential BLA submission for VYD2311 in children aged 0-11, though that trial will proceed only if DECLARATION succeeds.¹

On finances, PEMGARDA net product revenue was $14.3 million for the quarter, up from $11.8 million a year earlier, a 21% increase driven by patient demand.¹ Cash and cash equivalents stood at $160.1 million as of June 30, 2026, which the company said is expected to provide runway through the DECLARATION pivotal data readout and support potential commercial launch readiness for VYD2311.¹